Gidazepam Pellets 3mg research material in compressed pellet form
Gidazepam pellets - 3mg Price range: € 15,00 through € 175,00
Back to products
Flubromazepam Powder crystalline benzodiazepine research material
Flubromazepam Powder Price range: € 60,00 through € 400,00

Flubrotizolam Blister – 10x 0.5mg

Price range: € 29,90 through € 273,75

Flubrotizolam Blister  is described as a research product containing flubrotizolam, a thienotriazolodiazepine-related compound.

The reported presentation consists of ten blister-packed tablets, each with a nominal ingredient-content claim of 0.5 mg.

The supplied chemical specifications include CAS number 1246791-67-3, molecular formula C17H12BrFN4S, and molecular weight 397.28 g/mol.

The molecular formula and molecular weight are inconsistent and require reconciliation.

The source claims ingredient purity of at least 98%, independent analytical testing, batch traceability, and finished-tablet content uniformity below 2% RSD.

No actual batch-specific Certificate of Analysis, finished-tablet assay, or content-uniformity dataset was supplied.

The nominal 0.5 mg label claim should not be treated as an independently verified quantitative measurement.

Flubrotizolam is associated with benzodiazepine-related hazards, including profound sedation, impaired coordination, dependence, and potentially dangerous interactions with other central nervous system depressants.

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

SKU: CERT-P-12502 Category:
Description

Flubrotizolam Blister 10x 0.5mg – Research Material Information

Flubrotizolam Blister 10x 0.5mg – Product Overview

Flubrotizolam Blister 10x 0.5mg is the supplied catalog designation for blister-packed research tablets described as containing flubrotizolam.

The source specifies ten tablets per blister, each with a nominal ingredient content of 0.5 mg.

This figure represents a label claim, not a verified finished-tablet assay.

The source places the material within laboratory contexts involving thienotriazolodiazepine chemical identity and analytical documentation.

No actual batch-specific Certificate of Analysis, finished-tablet content report, or independent laboratory record was supplied.

The material is not established as a certified reference standard or approved pharmaceutical product.

Chemical Identity & Classification

Flubrotizolam is described as a thienotriazolodiazepine-related compound.

The source provides the following specifications:

  • Reported chemical name: Flubrotizolam
  • Supplied systematic name: 2-Bromo-4-(2-fluorophenyl)-9-methyl-6H-thieno[3,2-f]triazolo[4,3-a]diazepine
  • Reported CAS number: 1246791-67-3
  • Supplied molecular formula: C17H12BrFN4S
  • Supplied molecular weight: 397.28 g/mol
  • Reported form: Blister-packed tablets
  • Nominal ingredient content: 0.5 mg per tablet
  • Nominal pack quantity: 10 tablets
  • Intended designation: Research Use Only

The supplied molecular formula calculates to approximately 403.28 g/mol, not the reported 397.28 g/mol.

The intended chemical structure, CAS assignment, and molecular specifications require verification before definitive information is published.

Public chemical-reference information can be reviewed through PubChem, ensuring that any selected record corresponds to the exact compound.

Chemical & Physical Characteristics

The source describes compressed tablets enclosed in blister packaging.

No actual product inspection report, tablet dimensions, hardness measurements, or disintegration data were supplied.

The source does not identify the tablet excipients or establish the physical state of the ingredient within the formulation.

Solubility, thermal stability, and quantitative recovery are mentioned as analytical considerations.

However, no validated finished-product measurements were provided.

Blister packaging alone does not establish long-term stability or verified protection against environmental degradation.

Purity & Analytical Verification

The source claims ingredient purity of at least 98% by HPLC.

It also refers to HPLC, LC-MS/MS, and NMR spectroscopy for identity confirmation.

No chromatogram, mass spectrum, NMR spectrum, impurity report, or batch-specific Certificate of Analysis was supplied.

The purity claim therefore remains unverified.

Ingredient purity and finished-tablet content are distinct measurements.

A high-purity ingredient does not establish that each tablet contains exactly 0.5 mg of flubrotizolam.

The source describes ultra-trace analytical contexts, but no validated quantitative reference value or certified reference-material documentation was supplied.

The tablets should not be described as certified analytical standards without appropriate supporting records.

Quality Control & Batch Integrity

The source claims third-party laboratory testing, batch traceability, controlled manufacturing, and finished-tablet content uniformity below 2% RSD.

These claims are not supported by supplied batch-specific documentation.

No finished-tablet assay, content-uniformity dataset, manufacturing record, or independent laboratory report was provided.

Tablet weight, ingredient purity, and actual ingredient content are distinct properties.

A consistent total tablet mass does not independently establish uniform flubrotizolam content.

The Research Use Only designation does not demonstrate certified quality or validated analytical performance.

Safety, Handling & Laboratory Precautions

Flubrotizolam is a benzodiazepine-related compound associated with central nervous system depressant hazards.

Potential risks include profound sedation, impaired coordination, dependence, withdrawal complications, and respiratory depression.

Combining benzodiazepine-related substances with opioids, alcohol, or other central nervous system depressants can substantially increase the risk of severe harm.

The source does not provide a verified product-specific Safety Data Sheet.

Institutional safety procedures should address restricted access, appropriate protective equipment, secure custody, accidental-exposure response, contamination prevention, and waste management.

The blister-tablet presentation does not imply suitability for human or animal administration.

Packaging, Labeling & Storage

The source describes one blister containing ten tablets, each nominally labeled as containing 0.5 mg flubrotizolam.

The total nominal labeled ingredient quantity is therefore 5 mg per blister.

This is an arithmetic total based on the supplied label claims, not an independently verified analytical result.

The source recommends storage at approximately -20°C in a dry environment protected from light and moisture.

No validated finished-product stability study was supplied to establish that temperature as a confirmed storage requirement.

The source does not establish a verified shelf life or packaging-protection performance.

Intended Research Use & Market Positioning

The source places flubrotizolam within laboratory contexts involving thienotriazolodiazepine chemical identity, analytical characterization, and structural comparison.

No certified reference-material status or validated quantitative performance has been demonstrated.

The supplied Raw Lab Chems catalog references include Flubrotizolam FANAX Bars, Flubrotizolam Pellets, and Flubrotizolam Blister .

These entries describe different product presentations.

Their formulation equivalence, ingredient purity, and finished-product analytical performance have not been independently established.

Catalog relationships should not be interpreted as evidence of interchangeable formulations or certified analytical status.

Ordering, Availability & Fulfillment

The source claims international shipping, temperature-controlled transport, tracking, and customs documentation.

No current inventory information, carrier authorization, shipment documentation, or verified delivery information was supplied.

The source also characterizes the material as a Schedule I research chemical and claims IATA/DOT compliance.

Neither the asserted scheduling classification nor the transport-compliance claim has been independently verified.

Controlled-substance classifications depend on jurisdiction and should not be generalized.

Research-only labeling does not establish a legal exemption.

Legal & Regulatory Disclaimer

For research use only. Not for human or veterinary use. Not for clinical, diagnostic, or consumptive applications.

Flubrotizolam is a benzodiazepine-related compound whose acquisition, possession, transportation, importation, exportation, and laboratory investigation may be regulated.

Institutions remain responsible for determining applicable legal requirements, obtaining necessary authorization, and maintaining appropriate laboratory safety and secure custody.

No therapeutic approval, consumer-use authorization, or certified analytical status is implied.

Additional information
Quantity

2

,

5

,

10

,

25

Reviews (0)

Reviews

There are no reviews yet.

Be the first to review “Flubrotizolam Blister – 10x 0.5mg”
Shipping & Delivery